首頁 > 市場調查報告書 > 生物科技 > 生物科技應用在癌症治療的市場

聯絡我們?

市場調查報告書

生物科技應用在癌症治療的市場

Beyond Chemotherapy Battling Cancer with Biotechnology

出版商	BCC Research
出版日期	2004年12月	商品編碼	25570
內容資訊	英文 259 Pages
價格	本報告書已不再販售

簡介
目錄
相關商品

本報告已在2011年07月19日停止出版。

簡介

過去數十年的癌症治療主要是以化療為主，但是卻沒有達到預期的效果。直至最近生物醫藥品及單株抗體才受到許可，癌症治療也終於露出一線曙光。利用生物科技從事癌症治療的全球市場，從 2003 年的 150 億美金開始平均每年以 14.5% 的速度成長，一般預料將會在 2008 年達到 290 億美金的市場規模。

在多樣的產業部門中專精於成長市場之戰略性調查的調查公司 Business Communications Co., Inc. (總公司: 康乃迪克州)，詳盡地調查與分析生物科技應用在癌症治療的全球市場，並有系統地出版綜合報告書 "Beyond Chemotherapy: Battling Cancer with Biotechnology"。

此報告書使用包括 67張圖表在內的 259 頁篇幅，專門針對在 2004 年春天進行臨床實驗的主要生物醫藥品，除了分析其作用結構、開發企業檔案、相關規範及生物醫藥品市場的現況；也提供至 2008 年前的未來預測情報等。此報告書的概略架構如下所示。

1. 說明

2. 摘要

3. 概要

統計數據
癌症病因
癌症治療的現狀
利用生物醫藥品進行癌症撲滅策略
生物醫藥品的分類
相關規範

4. 生物醫藥品在癌症治療上的用途

癌症的分類
- 膀胱癌
- 腦腫瘤
- 乳癌
- 子宮頸癌
- 大腸癌
- 胃癌
- 頭頸部癌
- 腎臟癌
- 白血病與淋巴瘤
- 肝癌
- 肺癌
- 多發性骨髓癌
- 神經母細胞瘤
- 卵巢癌、子宮癌
- 胰臟癌
- 攝護腺癌
- 肉瘤
- 皮膚癌
- 化療的相關疾病
使用生物醫藥品治療癌症的一覽表
- 經許可使用在癌症治療的生物醫藥品概要
- 未來銷售預測概要

5. 生物醫藥品及其替代品

大分子
- 單株抗體
- T 細胞受體
- 荷爾蒙藥、細胞素藥
- 其他蛋白質藥劑
- 胜藥劑
- 核甘酸藥劑
疫苗療法( 37 藥劑)
病毒性生物醫藥品( 14 藥劑)

6. 產業結構

產業結構
企業檔案( 75 家)

Global revenues from biotech-enabled cancer therapies are expected to rise at an AAGR (average annual growth rate) of 14.5% from $15 billion in 2003 to more than $29 billion in 2008.
The market is being given a strong boost by demographics: cancer risk increases rapidly after age 55, and the baby boom generation is near that marker.
Biopharmaceuticals used to treat chemotherapy-related conditions, the weakest oncological growth category, is the strongest in terms of absolute sales. This is a fairly mature market whose potential will fade as less toxic cancer treatments are found.
Recent approvals for Avastin? and Erbitux? will help swell the growth rate of solid tumor biopharmaceutical therapies.

Projected Global Revenues from Biotech-enabled
Cancer Therapies by Application Type, through 2008
($ Millions)

Source: BCC, Inc.

INTRODUCTION

In 1971, U.S. President Richard Nixon declared a "War on Cancer" and congress passed the National Cancer Act, committing the nation to putting an end to this collection of dread diseases. More than 30 years later, the incidence of cancer is about the same as it was in 1950 and chances of survival are not much better.

For decades, cancer therapy has been dominated by chemotherapy. Unfortunately, for most cancers, chemotherapy does not work very well, if at all. Diagnosis of pancreatic cancer or liver cancer, for example, essentially is a death warrant, and most cancers have poor prognosis unless they are found really early. The recent approvals of biopharmaceuticals like Avastin?, Erbitux? and Herceptin?, all monoclonal antibody drugs, have given hope that the tide finally is turning.

Monoclonal antibodies are not the only tricks available in the biotechnology tool chest. It includes protein hormones and cytokines, antisense oligonucleotides, gene therapy, oncolytic viruses and cancer vaccines. Biopharmaceuticals approved so far for oncology indications are of three general types: monoclonal antibodies, colony stimulating factors and peptide hormone analogues. Other biopharmaceuticals, such as oligonucleotides, gene therapies, therapeutic vaccines, or oncolytic viruses have yet to be approved in major markets.

The promise of biotechnology finally is being brought to bear on this most problematic of diseases and its many manifestations. It appears, therefore, to be a propitious time to report on therapies being developed and assess the likelihood for success of these new therapies. This BCC report does just that, quantifying historical and projected sales for biopharmaceutical products to treat cancer.

SCOPE OF STUDY

The report:

Identifies all major biopharmaceuticals that were in clinical trials to treat cancer as of the spring of 2004
Describes these biopharmaceuticals and their proposed mechanisms of action
Identifies and profiles companies involved in developing biopharmaceuticals
Discusses regulatory policies that affect the development of biopharmaceuticals
Estimates current markets for biopharmaceutical drugs and project future sales five years out, through 2008.

METHODOLOGY AND INFORMATION SOURCES

The information reported herein has been gathered from a variety of industry and other sources. The 10K forms and other SEC filings from public companies have been examined along with annual reports, catalogues, press releases et cetera. Clinical trial information on cancer drugs was retrieved from the OVID database. The World Wide Web is a rich source of information, as almost every commercial concern now has its own web page. Much statistical information was garnered from the American Cancer Society, the Federal government and the World Health Organization.

Armed with the industry and statistical information garnered above, market participants have been interviewed as necessary to fill in the gaps of our understanding.

�@

INTRODUCTION

REASON FOR DOING STUDY
STUDY GOAL AND OBJECTIVES
WHO SHOULD READ THIS REPORT
METHODOLOGY AND INFORMATION SOURCES
ANALYSTS CREDENTIALS
OTHER RELEVANT RELATED BCC REPORTS AND PUBLICATIONS
BCC ON-LINE SERVICES
DISCLAIMER

EXECUTIVE SUMMARY

Summary Table:
PROJECTED GLOBAL REVENUES FROM BIOTECH-ENABLED CANCER THERAPIES BY APPLICATION TYPE, THROUGH 2008 ($ MILLION)
Summary Figure:
PROJECTED GLOBAL REVENUES FROM BIOTECH-ENABLED CANCER THERAPIES BY APPLICATION TYPE, THROUGH 2008 ($ MILLION)

OVERVIEW

GRIM STATISTICS
CAUSES OF CANCER
CURRENT CANCER TREATMENTS
- CHEMOTHERAPY

Table 1 ADVERSE EVENTS RELATED TO CHEMOTHERAPY
- STRATEGIES TO KILL CANCER USING BIOPHARMACEUTICALS
Table 2 STRATEGIES FOR TREATING CANCER WITH SELECTED BIOPHARMACEUTICALS
Table 2 (CONTINUED)
Table 3 SELECTED TUMOR ANTIGENS AND IMMUNOTHERAPIES
Table 3 (CONTINUED)
Table 4 SELECTED BIOPHARMACEUTICALS AS RADIOTHERAPEUTICS
Table 4 (CONTINUED)
- TYPES OF BIOPHARMACEUTICALS
  - MACROMOLECULES
    - Monoclonal Antibodies
    - Hormones and Cytokines
    - Other Protein Drugs
    - Peptides
    - Oligonucleotides
Table 5 SELECTED OLIGONUCLEOTIDE ANTISENSE DRUG CANDIDATES
Table 5 (CONTINUED)
- REGULATION
  - REGULATION IN THE U.S.
    - Drugs and Biologicals
Table 6 STAGES OF DRUG CANDIDATE REVIEW

APPLICATIONS FOR BIOPHARMACEUTICALS IN CANCER TREATMENT

TYPES OF CANCER

Table 7 INCIDENCE OF CANCER BY TYPE AND GENDER IN THE U.S., 2004
Table 8 BIOPHARMACEUTICAL DRUG CANDIDATES FOR BLADDER CANCER
Table 9 BIOPHARMACEUTICALS AS BRAIN CANCER THERAPIES
Table 10 BIOPHARMACEUTICALS APPROVED TO TREAT BREAST CANCER
Table 11 BIOPHARMACEUTICAL PIPELINE FOR BREAST CANCER
Table 11 (CONTINUED)
Table 12 GLOBAL REVENUES FROM BREAST CANCER BIOPHARMACEUTICALS, THROUGH 2008 ($ MILLION)
Figure 1 GLOBAL REVENUES FROM BREAST CANCER BIOPHARMACEUTICALS, 2004 AND 2008 ($ MILLION)
Table 13 BIOPHARMACEUTICAL PIPELINE TO TREAT CERVICAL CANCER
Table 14 BIOPHARMACEUTICALS APPROVED TO TREAT COLORECTAL CANCER
Table 15 BIOPHARMACEUTICAL THERAPIES FOR COLORECTAL CANCER IN CLINICAL TRIALS
Table 15 (CONTINUED)
Table 16 GLOBAL REVENUES FROM BIOPHARMACEUTICALS TO TREAT COLORECTAL CANCER, THROUGH 2008 ($ MILLION)
Figure 2 GLOBAL REVENUES FROM BIOPHARMACEUTICALS TO TREAT COLORECTAL CANCER, 2004 AND 2008 ($ MILLION)
Table 17 BIOPHARMACEUTICAL PIPELINE FOR TREATMENT OF GASTRIC CANCER
Table 18 GLOBAL REVENUES FROM BIOPHARMACEUTICALS TO TREAT GASTRIC CANCER, THROUGH 2008 ($ MILLION)
Table 19 BIOPHARMACEUTICAL PIPELINE TO TREAT HEAD AND NECK CANCER
Table 20 GLOBAL REVENUES FROM BIOPHARMACEUTICALS TO TREAT HEAD AND NECK CANCER, THROUGH 2008 ($ MILLION)
Table 21 BIOPHARMACEUTICALS APPROVED TO TREAT KIDNEY CANCER
Table 22 BIOPHARMACEUTICAL PIPELINE TO TREAT KIDNEY CANCER
Table 23 GLOBAL REVENUES FROM BIOPHARMACEUTICALS TO TREAT KIDNEY CANCER, THROUGH 2008 ($ MILLION)
Figure 3 GLOBAL REVENUES FROM BIOPHARMACEUTICALS TO TREAT KIDNEY CANCER, 2004 AND 2008 ($ MILLION)
Table 24 BIOPHARMACEUTICALS APPROVED TO TREAT LEUKEMIA OR LYMPHOMA
Table 25 BIOPHARMACEUTICAL PIPELINE TO TREAT LEUKEMIA AND LYMPHOMA
Table 26 GLOBAL REVENUES DERIVED FROM PHARMACEUTICALS TO TREAT LEUKEMIA AND LYMPHOMA, THROUGH 2008 ($ MILLION)
Figure 4 GLOBAL REVENUES DERIVED FROM PHARMACEUTICALS TO TREAT LEUKEMIA AND LYMPHOMA, 2001-2008 ($ MILLION)
Table 27 BIOPHARMACEUTICAL DRUG CANDIDATES TO TREAT LIVER CANCER
Table 28 BIOPHARMACEUTICALS IN CLINICAL TRIALS TO TREAT LUNG CANCER
Table 28 (CONTINUED)
Table 29 BIOPHARMACEUTICALS IN DEVELOPMENT TO TREAT MULTIPLE MYELOMA
Table 30 BIOPHARMACEUTICAL DRUG CANDIDATES TO TREAT NEUROBLASTOMA
Table 31 BIOPHARMACEUTICALS IN DEVELOPMENT TO TREAT OVARIAN AND UTERINE CANCER
Table 32 BIOPHARMACEUTICALS TO TREAT PANCREATIC CANCER
Table 33 GLOBAL REVENUES FROM BIOPHARMACEUTICALS TO TREAT PANCREATIC CANCER, THROUGH 2008 ($ MILLIONS)
Table 34 BIOPHARMACEUTICAL PIPELINE TO TREAT PROSTATE CANCER
Table 35 GLOBAL REVENUES FROM PHARMACEUTICALS TO TREAT PROSTATE CANCER, THROUGH 2008 ($ MILLION)
Figure 5 GLOBAL REVENUES FROM PHARMACEUTICALS TO TREAT PROSTATE CANCER, 2004-2008 ($ MILLION)
Table 36 APPROVED BIOPHARMACEUTICAL SARCOMA THERAPIES
Table 37 BIOPHARMACEUTICAL PIPELINE OF SARCOMA THERAPIES
Table 38 BIOPHARMACEUTICALS APPROVED TO TREAT SKIN CANCER
Table 39 BIOPHARMACEUTICAL PIPELINE TO TREAT SKIN CANCER
Table 39 (CONTINUED)
Table 40 GLOBAL REVENUES FROM BIOPHARMACEUTICALS TO TREAT SKIN CANCER, THROUGH 2008 ($ MILLIONS)
Figure 6 GLOBAL REVENUES FROM BIOPHARMACEUTICALS TO TREAT SKIN CANCER, 2001-2008 ($ MILLIONS)
Table 41 APPROVED BIOPHARMACEUTICALS TO TREAT CHEMOTHERAPY-RELATED CONDITIONS
Table 42 GLOBAL REVENUES FROM BIOPHARMACEUTICALS TO TREAT CHEMOTHERAPY RELATED CONDITIONS, THROUGH 2008
Figure 7 GLOBAL REVENUES FROM BIOPHARMACEUTICALS TO TREAT CHEMOTHERAPY RELATED CONDITIONS, 2001-2008
- SUMMARY TABLES - BIOPHARMACEUTICAL CANCER TREATMENTS
  - SUMMARY APPROVED BIOPHARMACEUTICALS FOR CANCER
Table 43 BIOPHARMACEUTICALS APPROVED TO TREAT ONCOLOGY INDICATIONS
Table 44 SUMMARY OF PROJECTED GLOBAL REVENUES FROM BIOTECH-ENABLED CANCER THERAPIES BY CANCER TYPE, THROUGH 2008 ($ MILLION)

BIOPHARMACEUTICAL DRUGS OR DRUG CANDIDATES

MACROMOLECULES
- MONOCLONAL ANTIBODIES
  - Product Pipieline

Table 45 FDA-APPROVED MONOCLONAL ANTIBODY THERAPIES FOR CANCER
Table 46 GLOBAL REVENUES FROM ANTIBODY THERAPIES FOR CANCER INDICATIONS, THROUGH 2008 ($ MILLION)
Figure 8 GLOBAL REVENUES FROM ANTIBODY THERAPIES FOR CANCER INDICATIONS, 2004 AND 2008 ($ MILLION)
Table 47 MONOCLONAL ANTIBODIES UNDER DEVELOPMENT AS ONCOLOGY DRUGS
Table 47 (CONTINUED)
Table 48 GLOBAL REVENUES DERIVED FROM HORMONE OR CYTOKINE ONCOLOGY DRUGS, THROUGH 2008 ($ MILLION)
Figure 9 GLOBAL REVENUES DERIVED FROM HORMONE OR CYTOKINE ONCOLOGY DRUGS, 2001-2008 ($ MILLION)
Table 49 HORMONE AND CYTOKINE DRUGS AND DRUG CANDIDATES
Table 50 PEPTIDE DRUG CANDIDATES FOR ONCOLOGY INDICATIONS
Table 51 OLIGONUCLEOTIDE DRUG CANDIDATES FOR CANCER INDICATIONS
Table 51 (CONTINUED)
- VACCINE THERAPIES
Table 52 SELECTED THERAPEUTIC VACCINE CANDIDATES FOR ONCOLOGY INDICATIONS
Table 52 (CONTINUED)
- VIRUS BASED BIOPHARMACEUTICALS
Table 53 VIRUS-BASED BIOPHARMACEUTICALS FOR ONCOLOGY INDICATIONS
Table 54 INDICATIONS FOR WHICH ADVEXIN IS BEING TESTED

STRUCTURE OF THE INDUSTRY

STRUCTURE OF THE INDUSTRY

Table 55 BIOTECHNOLOGY COMPANIES WITH APPROVED ONCOLOGY PRODUCTS
Table 56 ONCOLOGY BIOPHARMACEUTICAL MARKET LEADERS WORLDWIDE, 2003 SALES ($ BILLIONS)
- COMPANY PROFILES
  - ABGENIX
  - AGENNIX
  - ALTAREX CORP.
  - ALTOR BIOSCIENCE
  - AMGEN
  - ANTIGENICS
  - ANTISENSE PHARMA GMBH
  - APHTON
  - APTAMERA
  - ATTENUON, LLC
  - AVAX TECHNOLOGIES
  - ASTRAZENECA
  - AVENTIS SA
  - AVI BIOPHARMA
  - AVIDEX
  - BIOGEN IDEC
  - BIOMIRA
  - BIOVEX LTD.
  - BOSTON LIFE SCIENCES
  - CALLISTO PHARMACEUTICALS
  - CANCERVAX
  - CELL GENESYS
  - COLEY PHARMACEUTICAL GROUP
  - CORIXA
  - CURIS, INC.
  - CYTHERIS
  - CYTOGEN
  - CYTOGENIX
  - DIADEXU.S.
  - DYNAVAX
  - ENZON
  - EPEIUS BIOTECHNOLOGIES
  - FAVRILLE
  - GENENTECH
  - GENMAB A/S
  - GENTA
  - GENVEC
  - GENZYME
  - GERON
  - GLAXOSMITHKLINE
  - IDM, INC.
  - IMCLONE SYSTEMS, INC.
  - INGENEON
  - ILEX ONCOLOGY
  - IMMUNOGEN
  - IMMUNOMEDICS
  - INSMED
  - INTROGEN THERAPEUTICS
  - ISIS PHARMACEUTICALS, INC.
  - JOHNSON AND JOHNSON
  - MAXCYTE
  - MEDAREX
  - MEDIMMUNE
  - MERCK KGAA
  - METHYLGENE
  - MGI PHARMA
  - MOLECULAR ENGINES LABORATORIES
  - MORPHOTEK
  - NEOPHARM
  - ONCOGENEX TECHNOLOGIES
  - PANACEA PHARMACEUTICALS, INC.
  - PHARMEXA
  - PROGENICS PHARMACEUTICALS
  - PROTEIN DESIGN LABS
  - RAVEN BIOTECHNOLOGIES
  - REGENERON
  - ROCHE GROUP
  - SEATTLE GENETICS
  - STRESSGEN
  - THERION BIOLOGICS
  - TRANSMOLECULAR
  - U3 PHARMA
  - WYETH
  - XCYTE THERAPIES
  - XENOVA GROUP, PLC

LIST OF TABLES

Summary Table: PROJECTED GLOBAL REVENUES FROM BIOTECH-ENABLED CANCER THERAPIES BY APPLICATION TYPE, THROUGH 2008 ($ MILLION)
Table 1 ADVERSE EVENTS RELATED TO CHEMOTHERAPY
Table 2 STRATEGIES FOR TREATING CANCER WITH SELECTED BIOPHARMACEUTICALS
Table 3 SELECTED TUMOR ANTIGENS AND IMMUNOTHERAPIES
Table 4 SELECTED BIOPHARMACEUTICALS AS RADIOTHERAPEUTICS
Table 5 SELECTED OLIGONUCLEOTIDE ANTISENSE DRUG CANDIDATES
Table 6 STAGES OF DRUG CANDIDATE REVIEW
Table 7 INCIDENCE OF CANCER BY TYPE AND GENDER IN THE U.S., 2004
Table 8 BIOPHARMACEUTICAL DRUG CANDIDATES FOR BLADDER CANCER
Table 9 BIOPHARMACEUTICALS AS BRAIN CANCER THERAPIES
Table 10 BIOPHARMACEUTICALS APPROVED TO TREAT BREAST CANCER
Table 11 BIOPHARMACEUTICAL PIPELINE FOR BREAST CANCER
Table 12 GLOBAL REVENUES FROM BREAST CANCER BIOPHARMACEUTICALS, THROUGH 2008 ($ MILLION)
Table 13 BIOPHARMACEUTICAL PIPELINE TO TREAT CERVICAL CANCER
Table 14 BIOPHARMACEUTICALS APPROVED TO TREAT COLORECTAL CANCER
Table 15 BIOPHARMACEUTICAL THERAPIES FOR COLORECTAL CANCER IN CLINICAL TRIALS
Table 16 GLOBAL REVENUES FROM BIOPHARMACEUTICALS TO TREAT COLORECTAL CANCER, THROUGH 2008 ($ MILLION)
Table 17 BIOPHARMACEUTICAL PIPELINE FOR TREATMENT OF GASTRIC CANCER
Table 18 GLOBAL REVENUES FROM BIOPHARMACEUTICALS TO TREAT GASTRIC CANCER, THROUGH 2008 ($ MILLION)
Table 19 BIOPHARMACEUTICAL PIPELINE TO TREAT HEAD AND NECK CANCER
Table 20 GLOBAL REVENUES FROM BIOPHARMACEUTICALS TO TREAT HEAD AND NECK CANCER, THROUGH 2008 ($ MILLION)
Table 21 BIOPHARMACEUTICALS APPROVED TO TREAT KIDNEY CANCER
Table 22 BIOPHARMACEUTICAL PIPELINE TO TREAT KIDNEY CANCER
Table 23 GLOBAL REVENUES FROM BIOPHARMACEUTICALS TO TREAT KIDNEY CANCER, THROUGH 2008 ($ MILLION)
Table 24 BIOPHARMACEUTICALS APPROVED TO TREAT LEUKEMIA OR LYMPHOMA
Table 25 BIOPHARMACEUTICAL PIPELINE TO TREAT LEUKEMIA AND LYMPHOMA
Table 26 GLOBAL REVENUES DERIVED FROM PHARMACEUTICALS TO TREAT LEUKEMIA AND LYMPHOMA, THROUGH 2008 ($ MILLION)
Table 27 BIOPHARMACEUTICAL DRUG CANDIDATES TO TREAT LIVER CANCER
Table 28 BIOPHARMACEUTICALS IN CLINICAL TRIALS TO TREAT LUNG CANCER
Table 29 BIOPHARMACEUTICALS IN DEVELOPMENT TO TREAT MULTIPLE MYELOMA
Table 30 BIOPHARMACEUTICAL DRUG CANDIDATES TO TREAT NEUROBLASTOMA
Table 31 BIOPHARMACEUTICALS IN DEVELOPMENT TO TREAT OVARIAN AND UTERINE CANCER
Table 32 BIOPHARMACEUTICALS TO TREAT PANCREATIC CANCER
Table 33 GLOBAL REVENUES FROM BIOPHARMACEUTICALS TO TREAT PANCREATIC CANCER, THROUGH 2008 ($ MILLIONS)
Table 34 BIOPHARMACEUTICAL PIPELINE TO TREAT PROSTATE CANCER
Table 35 GLOBAL REVENUES FROM PHARMACEUTICALS TO TREAT PROSTATE CANCER, THROUGH 2008 ($ MILLION)
Table 36 APPROVED BIOPHARMACEUTICAL SARCOMA THERAPIES
Table 37 BIOPHARMACEUTICAL PIPELINE OF SARCOMA THERAPIES
Table 38 BIOPHARMACEUTICALS APPROVED TO TREAT SKIN CANCER
Table 39 BIOPHARMACEUTICAL PIPELINE TO TREAT SKIN CANCER
Table 40 GLOBAL REVENUES FROM BIOPHARMACEUTICALS TO TREAT SKIN CANCER, THROUGH 2008 ($ MILLIONS)
Table 41 APPROVED BIOPHARMACEUTICALS TO TREAT CHEMOTHERAPY-RELATED CONDITIONS
Table 42 GLOBAL REVENUES FROM BIOPHARMACEUTICALS TO TREAT CHEMOTHERAPY RELATED CONDITIONS, THROUGH 2008
Table 43 BIOPHARMACEUTICALS APPROVED TO TREAT ONCOLOGY INDICATIONS
Table 44 SUMMARY OF PROJECTED GLOBAL REVENUES FROM BIOTECH-ENABLED CANCER THERAPIES BY CANCER TYPE, THROUGH 2008 ($ MILLION)
Table 45 FDA-APPROVED MONOCLONAL ANTIBODY THERAPIES FOR CANCER
Table 46 GLOBAL REVENUES FROM ANTIBODY THERAPIES FOR CANCER INDICATIONS, THROUGH 2008 ($ MILLION)
Table 47 MONOCLONAL ANTIBODIES UNDER DEVELOPMENT AS ONCOLOGY DRUGS
Table 48 GLOBAL REVENUES DERIVED FROM HORMONE OR CYTOKINE ONCOLOGY DRUGS, THROUGH 2008 ($ MILLION)
Table 49 HORMONE AND CYTOKINE DRUGS AND DRUG CANDIDATES
Table 50 PEPTIDE DRUG CANDIDATES FOR ONCOLOGY INDICATIONS
Table 51 OLIGONUCLEOTIDE DRUG CANDIDATES FOR CANCER INDICATIONS
Table 52 SELECTED THERAPEUTIC VACCINE CANDIDATES FOR ONCOLOGY INDICATIONS
Table 53 VIRUS-BASED BIOPHARMACEUTICALS FOR ONCOLOGY INDICATIONS
Table 54 INDICATIONS FOR WHICH ADVEXIN IS BEING TESTED
Table 55 BIOTECHNOLOGY COMPANIES WITH APPROVED ONCOLOGY PRODUCTS
Table 56 ONCOLOGY BIOPHARMACEUTICAL MARKET LEADERS WORLDWIDE, 2003 SALES ($ BILLIONS)

LIST OF FIGURES

Summary Figure: PROJECTED GLOBAL REVENUES FROM BIOTECH-ENABLED CANCER THERAPIES BY APPLICATION TYPE, THROUGH 2008 ($ MILLION)
Figure 1 GLOBAL REVENUES FROM BREAST CANCER BIOPHARMACEUTICALS, 2004 AND 2008 ($ MILLION)
Figure 2 GLOBAL REVENUES FROM BIOPHARMACEUTICALS TO TREAT COLORECTAL CANCER, 2004 AND 2008 ($ MILLION)
Figure 3 GLOBAL REVENUES FROM BIOPHARMACEUTICALS TO TREAT KIDNEY CANCER, 2004 AND 2008 ($ MILLION)
Figure 4 GLOBAL REVENUES DERIVED FROM PHARMACEUTICALS TO TREAT LEUKEMIA AND LYMPHOMA, 2001-2008 ($ MILLION)
Figure 5 GLOBAL REVENUES FROM PHARMACEUTICALS TO TREAT PROSTATE CANCER, 2004-2008 ($ MILLION)
Figure 6 GLOBAL REVENUES FROM BIOPHARMACEUTICALS TO TREAT SKIN CANCER, 2001-2008 ($ MILLIONS)
Figure 7 GLOBAL REVENUES FROM BIOPHARMACEUTICALS TO TREAT CHEMOTHERAPY RELATED CONDITIONS, 2001-2008
Figure 8 GLOBAL REVENUES FROM ANTIBODY THERAPIES FOR CANCER INDICATIONS, 2004 AND 2008 ($ MILLION)
Figure 9 GLOBAL REVENUES DERIVED FROM HORMONE OR CYTOKINE ONCOLOGY DRUGS, 2001-2008 ($ MILLION)

簡介
目錄
相關商品

使用指南產品及服務須知網站導覽

星期一到星期五 / 9:30am - 6:00pm
TEL: 02-2729-4219 (+886-2-2729-4219)
E-mail: tw-info@gii.co.jp

生物科技應用在癌症治療的市場

Beyond Chemotherapy Battling Cancer with Biotechnology